

CITATION REPORT

List of articles citing

Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

DOI: 10.1007/s40273-018-0732-4
Pharmacoeconomics, 2019, 37, 239-253.

Source: <https://exaly.com/paper-pdf/74567775/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
10	Midostaurin cost effective for FLT3-mutated AML. <i>Pharmacoeconomics & Outcomes News</i> , 2018 , 816, 21-21	0.1	
9	Healthcare expenses for treatment of acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2019 , 12, 641-650	2.8	9
8	Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?. <i>Current Hematologic Malignancy Reports</i> , 2019 , 14, 171-178	4.4	11
7	Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids. <i>Molecular Cancer Research</i> , 2021 , 19, 812-822	6.6	1
6	Two decades of targeted therapies in acute myeloid leukemia. <i>Leukemia</i> , 2021 , 35, 651-660	10.7	13
5	Cost-effectiveness of gilteritinib for relapsed/refractory acute myeloid leukemia. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1469-1481	1.9	2
4	Policy in Clinical Practice: Emergency Medicaid and Access to Allogeneic Stem Cell Transplant for Undocumented Immigrants. <i>Journal of Hospital Medicine</i> , 2021 ,	2.7	
3	Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2021 ,	4	1
2	Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia.. <i>Expert Review of Hematology</i> , 2022 ,	2.8	1
1	A systematic review of economic evaluations for the pharmaceutical treatment of chronic lymphocytic leukemia and acute myeloid leukemia. 2022 , 15, 833-847		0